BLB offers you the possibility to test your drug candidates in a human liver biological system: the unique and patent-protected ExoLiver platform
ExoLiver mimics the human liver microenvironment through the combination of co-culture of primary human liver cells, constant stimulation of the endothelial cell layer with microfluidic shear stress, and continuous paracrine interactions between all cell types. Due to its cutting-edge characteristics, ExoLiver has extremely high versatility allowing its use as experimental model to deeply characterize liver diseases pathophysiology, to understand the mechanisms of action of new chemical entities, or to investigate the possible hepatotoxicity of novel compounds.
ExoLiver, which allows co-culture ofhealthy or diseased hepatic cellsunravels key biological data obtained in a human-like system, therefore representing the ultimate pre-clinical step in your development pipeline.
The complete pre-clinical Solution
BLB works toward helping our partners to accelerate the development of new chemical entities to treat human liver disease. We value talent, experience and dedication of each of our employees.
BLB seeks outstanding scientists, pharmacologists, biomedical engineers, computational biologists and business developers